Form 4: CONMED Corp VP-Corporate Controller Receives Stock Options

Terence M. Berge, VP-Corporate Controller of CONMED Corp, was granted 8,000 stock options under the company's 2018 Long-Term Incentive Plan.

Summary

• Terence M. Berge, VP-Corporate Controller at CONMED Corp, received 8,000 stock options on March 1, 2024.
• The options were granted under the company's 2018 Long-Term Incentive Plan.
• The exercise price of the options is $79.95.
• The options vest in equal amounts over a five-year period and expire on March 1, 2034.
• A Power of Attorney was executed on January 26, 2024, granting Heather L. Cohen, Lindsey F. Brewer, and Thomas Fistek the authority to act on behalf of Terence M. Berge for Section 16 and Rule 144 filings.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is therefore moderately positive.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the medical technology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry.
• Companies like Medtronic, Stryker, and Johnson & Johnson also utilize stock options to incentivize their executives.
• The vesting schedule of five years is fairly standard for such grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of investment in leadership.

Key Dates